Company
About Us
Management Team
Board of Directors
Study Collaborations
News and Resources
Careers
Technology
Single Cell Network Profiling (SCNP)
Unique Benefits
Applications of SCNP
Drug Development Applications
Drug Development Applications
Preclinical Development
Clinical Development
Partnership Strategy
Diagnostic Applications
Unmet Need
AML Induction Response Test Development
Scientific Publications
Papers
Posters and Presentations
About Us
Management Team
Board of Directors
Study Collaborations
News and Resources
Press Releases / Company News
Links
Careers
Press Releases / Company News
Date
Description
02/10/2012
Nodality and UCB Enter into a Multi-Year Strategic Collaboration
01/24/2011
Nodality Takes Top Honors as “Most Promising Company” at the Personalized Medicine World Conference 2011
12/13/2010
Nodality Appoints Dr. Greg Critchfield to Board of Directors
12/07/2010
Nodality Showcases Novel, Proprietary Technology to Predict Response to Therapy and Relapse Risk in Cancer Patients
11/29/2010
Nodality Announces Presentations at 2010 ASH, Including Key Findings in Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL)
07/16/2010
Nodality and Celgene Form Drug Development Collaboration
03/22/2010
Nodality Completes $15.5 Million in Financing
11/30/2009
Nodality Announces Data Presentations at 2009 ASH
03/16/2009
Nodality Completes Series B Financing
09/24/2007
Nodality Names David R. Parkinson, M.D. as Its CEO
02/01/2007
Nodality Raises Series A Financing
